Literature DB >> 8485808

Gas-chromatographic analysis of busulfan for therapeutic drug monitoring.

L Embree1, R B Burns, J R Heggie, G L Phillips, D E Reece, J J Spinelli, D O Hartley, N J Hudon, J H Goldie.   

Abstract

The development and validation of a gas chromatographic assay method for determination of total and free busulfan concentrations in human plasma for pharmacokinetic studies is reported. 1,6-Bis(methanesulfonyloxy)hexane, the internal standard, and a potential metabolite, 3-hydroxysulfolane, were synthesized. Plasma and plasma ultrafiltrate samples containing busulfan and internal standard were extracted with ethyl acetate and derivatized with 2,3,5,6-tetrafluorothiophenol prior to gas chromatographic determination. The 63Ni electron-capture detector provided a limit of detection of 0.0600 microgram/ml with a limit of quantitation of 0.100 microgram/ml busulfan in biological samples. Calibration curves were linear from 0.100 to 3.00 micrograms/ml in plasma (500 microliters) and 0.100 to 2.00 micrograms/ml in plasma ultrafiltrate (100 microliters). Extraction and derivatization yields ranged from 78.4% to 89.6% and 56.0% to 71.3%, respectively. Specificity of this assay for busulfan in the presence of its potential metabolites was demonstrated. Also, plasma samples containing co-administered drugs gave no response under these conditions. Clinical samples obtained following administration of a 1 mg/kg oral busulfan dose demonstrate the applicability of this method to analysis of total and free plasma concentrations.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8485808     DOI: 10.1007/bf00685617

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  28 in total

1.  Quantitation of busulfan in plasma by high-performance liquid chromatography using postcolumn photolysis.

Authors:  J Blanz; C Rosenfeld; B Proksch; G Ehninger; K P Zeller
Journal:  J Chromatogr       Date:  1990-11-16

2.  Influence of immunosuppression on acute liver toxicity after intensified conditioning regimens for bone marrow transplantation in children.

Authors:  W Emminger; W Emminger-Schmidmeier; C Peters; H Gadner
Journal:  Blood       Date:  1991-04-01       Impact factor: 22.113

3.  Measurement of busulfan in plasma by high-performance liquid chromatography.

Authors:  W D Henner; E A Furlong; M D Flaherty; T C Shea; W P Peters
Journal:  J Chromatogr       Date:  1987-05-15

4.  Gas chromatographic determination of busulfan in plasma with electron-capture detection.

Authors:  M Hassan; H Ehrsson
Journal:  J Chromatogr       Date:  1983-10-14

5.  The clinical course of 53 patients with venocclusive disease of the liver after marrow transplantation.

Authors:  G B McDonald; P Sharma; D E Matthews; H M Shulman; E D Thomas
Journal:  Transplantation       Date:  1985-06       Impact factor: 4.939

6.  Determination of busulfan in plasma by GC-MS with selected-ion monitoring.

Authors:  H Ehrsson; M Hassan
Journal:  J Pharm Sci       Date:  1983-10       Impact factor: 3.534

7.  Urinary metabolites of busulfan in the rat.

Authors:  M Hassan; H Ehrsson
Journal:  Drug Metab Dispos       Date:  1987 May-Jun       Impact factor: 3.922

8.  Busulfan, cyclophosphamide, and melphalan conditioning for autologous bone marrow transplantation in hematologic malignancy.

Authors:  G L Phillips; J D Shepherd; M J Barnett; P M Lansdorp; H G Klingemann; J J Spinelli; T J Nevill; K W Chan; D E Reece
Journal:  J Clin Oncol       Date:  1991-10       Impact factor: 44.544

9.  Acute toxicity and first clinical results of intensive postinduction therapy using a modified busulfan and cyclophosphamide regimen with autologous bone marrow rescue in first remission of acute myeloid leukemia.

Authors:  D W Beelen; K Quabeck; U Graeven; H G Sayer; H K Mahmoud; U W Schaefer
Journal:  Blood       Date:  1989-10       Impact factor: 22.113

10.  Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia.

Authors:  R B Geller; R Saral; S Piantadosi; M Zahurak; G B Vogelsang; J R Wingard; R F Ambinder; W B Beschorner; H G Braine; W H Burns
Journal:  Blood       Date:  1989-06       Impact factor: 22.113

View more
  1 in total

Review 1.  The role of busulfan in bone marrow transplantation.

Authors:  M Hassan
Journal:  Med Oncol       Date:  1999-09       Impact factor: 3.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.